Published in Ther Adv Musculoskelet Dis on August 01, 2013
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci (2015) 0.80
The quality of health care delivered to adults in the United States. N Engl J Med (2003) 50.33
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg (2005) 7.36
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med (2011) 6.44
Incidence and mortality of hip fractures in the United States. JAMA (2009) 6.05
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA (2011) 5.33
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone (2004) 5.27
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med (2002) 4.20
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res (1995) 3.23
Bisphosphonates for osteoporosis. N Engl J Med (2010) 2.95
Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist (2004) 2.90
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Bisphosphonates: a review of their pharmacokinetic properties. Bone (1996) 2.52
Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc (2007) 2.43
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res (2012) 2.29
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology (2010) 2.14
Bisphosphonates: preclinical review. Oncologist (2004) 2.08
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 2.04
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc (2002) 1.97
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.92
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Osteoporosis in men. Endocr Rev (2008) 1.80
Bone density and fracture risk in men. J Bone Miner Res (1998) 1.77
Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med (2007) 1.62
Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab (2010) 1.60
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Bisphosphonate nephrotoxicity. Kidney Int (2008) 1.53
Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med (2003) 1.50
Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging (2007) 1.44
Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab (2012) 1.42
Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine (2009) 1.40
Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab (2012) 1.37
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res (2003) 1.34
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer (2007) 1.27
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone (2003) 1.24
Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab (2012) 1.19
Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos (2008) 1.19
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int (2003) 1.17
Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int (2009) 1.14
The kidney and bisphosphonates. Bone (2011) 1.14
Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. J Osteoporos (2011) 1.10
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab (2007) 1.07
Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int (2010) 1.07
Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res (2007) 1.05
Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res (2010) 1.02
The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab (2010) 0.99
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol (2009) 0.99
Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther (2010) 0.95
Seizures associated with zoledronic acid for osteoporosis. J Clin Endocrinol Metab (2011) 0.92
Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc (2011) 0.92
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int (2007) 0.91
Osteoporosis in men. J Osteoporos (2012) 0.88
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone (2011) 0.87
Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int (2010) 0.86
Male osteoporosis: deadly, but ignored. Am J Med Sci (2007) 0.85
Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU Int (2009) 0.85
A single infusion of zoledronate prevents bone loss after stroke. Stroke (2007) 0.84
Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer (2009) 0.84
Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab (2012) 0.82
Disability following hip fracture. Phys Ther (1994) 0.82
Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging (2009) 0.82
Skeletal safety of tiludronate. Bone (1995) 0.81
The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM (2008) 0.80
Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther (2010) 0.80
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res (2012) 2.85
Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc (2006) 2.33
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res (2006) 1.91
High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol (2011) 1.81
Osteoporosis in men. Endocr Rev (2008) 1.80
Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci (2012) 1.76
Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol (2007) 1.75
Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res (2003) 1.73
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab (2011) 1.71
Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int (2008) 1.71
Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol (2006) 1.63
Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med (2008) 1.53
Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med (2003) 1.50
Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. J Clin Endocrinol Metab (2005) 1.44
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int (2005) 1.35
Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res (2010) 1.35
Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol (2010) 1.34
The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab (2008) 1.29
Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res (2012) 1.28
Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res (2009) 1.13
Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. J Osteoporos (2011) 1.10
Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol (2008) 1.10
Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong). Osteoporos Int (2004) 1.09
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res (2011) 1.08
Epidemiology of rib fractures in older men: Osteoporotic Fractures in Men (MrOS) prospective cohort study. BMJ (2010) 1.05
Efficacy and safety of monthly ibandronate in men with low bone density. Bone (2010) 1.04
Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Hum Mol Genet (2014) 1.02
Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res (2011) 1.01
Thyroid function and mortality in older men: a prospective study. J Clin Endocrinol Metab (2012) 1.01
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. J Med Device (2013) 0.98
Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res (2014) 0.97
Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. J Bone Miner Res (2007) 0.96
Youth: a health plan-based lifestyle intervention increases bone mineral density in adolescent girls. Arch Pediatr Adolesc Med (2006) 0.94
Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc (2011) 0.92
Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control (2010) 0.91
Self-reported weight at birth predicts measures of femoral size but not volumetric BMD in eldery men: MrOS. J Bone Miner Res (2011) 0.89
Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol (2013) 0.89
Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom (2002) 0.88
Smoking predicts incident fractures in elderly men: Mr OS Sweden. J Bone Miner Res (2010) 0.88
Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res (2007) 0.87
Inferior physical performance tests in 10,998 men in the MrOS study is associated with recurrent falls. Age Ageing (2012) 0.87
Sex-specific effect of Pirin gene on bone mineral density in a cohort of 4000 Chinese. Bone (2009) 0.86
Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res (2013) 0.86
Inferior physical performance test results of 10,998 men in the MrOS Study is associated with high fracture risk. Age Ageing (2012) 0.86
Weekly oral alendronic Acid in male osteoporosis. Clin Drug Investig (2004) 0.86
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab (2015) 0.84
Serum insulin-like growth factor-I concentration is associated with leukocyte telomere length in a population-based cohort of elderly men. J Clin Endocrinol Metab (2009) 0.84
Obstructive sleep apnea during rapid eye movement sleep, daytime sleepiness, and quality of life in older men in Osteoporotic Fractures in Men (MrOS) Sleep Study. J Clin Sleep Med (2013) 0.84
Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab (2012) 0.84
Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men. Clin Chim Acta (2009) 0.83
Objective measures of physical activity, fractures and falls: the osteoporotic fractures in men study. J Am Geriatr Soc (2013) 0.83
Functional polymorphisms affecting the clinically important arginine-137 residue of AVPR2 do not influence serum sodium concentration at the population level. Physiol Genomics (2013) 0.83
Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging (2009) 0.82
Periosteal remodeling at the femoral neck in nonhuman primates. J Bone Miner Res (2006) 0.82
Relationship of Bone Metabolism Biomarkers and Periodontal Disease: The Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab (2015) 0.82
Serum estradiol is associated with lean mass in elderly Swedish men. Eur J Endocrinol (2010) 0.82
Calcium metabolism and cardiovascular function after spaceflight. J Appl Physiol (1985) (2002) 0.81
Vitamin D receptor 3' haplotypes are unequally expressed in primary human bone cells and associated with increased fracture risk: the MrOS Study in Sweden and Hong Kong. J Bone Miner Res (2007) 0.81
Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab (2007) 0.81
The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study. Cancer Epidemiol Biomarkers Prev (2009) 0.81
Heterozygosity for a coding SNP in COL1A2 confers a lower BMD and an increased stroke risk. Biochem Biophys Res Commun (2009) 0.80
Estimation of physical performance and measurements of habitual physical activity may capture men with high risk to fall--data from the Mr Os Sweden cohort. Arch Gerontol Geriatr (2008) 0.80
Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg (2011) 0.79
YOUTH: decisions and challenges in designing an osteoporosis prevention intervention for teen girls. Prev Med (2004) 0.79
Limited clinical utility of a genetic risk score for the prediction of fracture risk in elderly subjects. J Bone Miner Res (2015) 0.78
The role of 5α-reductase inhibition in men receiving testosterone replacement therapy. JAMA (2012) 0.78
Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med (2002) 0.78
Comparison of testosterone, alendronate, and a combination of both therapies in men with low bone mineral density. J Investig Med (2007) 0.78
Seasonal iodine deficiency in Latvian school children. Thyroid (2012) 0.77
There is in elderly men a group difference between fallers and non-fallers in physical performance tests. Age Ageing (2011) 0.77
Circulating vitamin D, supplement use, and cardiovascular disease risk: the MrOS Sleep Study. J Clin Endocrinol Metab (2014) 0.77
Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men. Clin Chem (2010) 0.77
International and ethnic variability of falls in older men. Scand J Public Health (2013) 0.76
Quality indicators for management of osteoporosis. Ann Intern Med (2002) 0.75
Absence of AVPR2 copy number variation in eunatremic and dysnatremic subjects in non-Hispanic Caucasian populations. Physiol Genomics (2009) 0.75
Fracture risk and zoledronic acid in men with osteoporosis. N Engl J Med (2013) 0.75
The impact of estradiol on bone mineral density is modulated by the specific estrogen receptor-alpha cofactor retinoblastoma-interacting zinc finger protein-1 insertion/deletion polymorphism. J Clin Endocrinol Metab (2007) 0.75
Images in clinical medicine. Adults with osteogenesis imperfecta. N Engl J Med (2006) 0.75
Creating an institutional resource for research education and career development: a novel model from Oregon Clinical and Translational Research Institute. Clin Transl Sci (2014) 0.75
Risk factors for diminished bone mineral density among male hemodialysis patients--a cross-sectional study. Arch Osteoporos (2012) 0.75